334 related articles for article (PubMed ID: 30112929)
1. Overcoming drug-resistant lung cancer by paclitaxel-loaded hyaluronic acid-coated liposomes targeted to mitochondria.
Tian Y; Zhang H; Qin Y; Li D; Liu Y; Wang H; Gan L
Drug Dev Ind Pharm; 2018 Dec; 44(12):2071-2082. PubMed ID: 30112929
[TBL] [Abstract][Full Text] [Related]
2. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.
Jiang L; Li L; He X; Yi Q; He B; Cao J; Pan W; Gu Z
Biomaterials; 2015 Jun; 52():126-39. PubMed ID: 25818419
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion.
Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y
Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386
[TBL] [Abstract][Full Text] [Related]
4. Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution.
Liu Y; Sun J; Lian H; Cao W; Wang Y; He Z
J Pharm Sci; 2014 May; 103(5):1538-47. PubMed ID: 24619562
[TBL] [Abstract][Full Text] [Related]
5. Tumor- and mitochondria-targeted nanoparticles eradicate drug resistant lung cancer through mitochondrial pathway of apoptosis.
Wang H; Zhang F; Wen H; Shi W; Huang Q; Huang Y; Xie J; Li P; Chen J; Qin L; Zhou Y
J Nanobiotechnology; 2020 Jan; 18(1):8. PubMed ID: 31918714
[TBL] [Abstract][Full Text] [Related]
6. Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment.
Assanhou AG; Li W; Zhang L; Xue L; Kong L; Sun H; Mo R; Zhang C
Biomaterials; 2015 Dec; 73():284-95. PubMed ID: 26426537
[TBL] [Abstract][Full Text] [Related]
7. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer.
Zhou J; Zhao WY; Ma X; Ju RJ; Li XY; Li N; Sun MG; Shi JF; Zhang CX; Lu WL
Biomaterials; 2013 May; 34(14):3626-38. PubMed ID: 23422592
[TBL] [Abstract][Full Text] [Related]
8. Formulation and evaluation of a two-stage targeted liposome coated with hyaluronic acid for improving lung cancer chemotherapy and overcoming multidrug resistance.
Wang X; Cai H; Huang X; Lu Z; Zhang L; Hu J; Tian D; Fu J; Zhang G; Meng Y; Zheng G; Chang C
J Biomater Sci Polym Ed; 2023 Oct; 34(14):1928-1951. PubMed ID: 37060335
[TBL] [Abstract][Full Text] [Related]
9. Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo.
Wang W; Xi M; Duan X; Wang Y; Kong F
Int J Nanomedicine; 2015; 10():3737-50. PubMed ID: 26045664
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-loaded redox-sensitive nanoparticles based on hyaluronic acid-vitamin E succinate conjugates for improved lung cancer treatment.
Song Y; Cai H; Yin T; Huo M; Ma P; Zhou J; Lai W
Int J Nanomedicine; 2018; 13():1585-1600. PubMed ID: 29588586
[TBL] [Abstract][Full Text] [Related]
11. Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance.
Lei M; Ma G; Sha S; Wang X; Feng H; Zhu Y; Du X
Drug Deliv; 2019 Dec; 26(1):262-272. PubMed ID: 30856352
[TBL] [Abstract][Full Text] [Related]
12. Investigation on vitamin e succinate based intelligent hyaluronic acid micelles for overcoming drug resistance and enhancing anticancer efficacy.
Hou L; Tian C; Chen D; Yuan Y; Yan Y; Huang Q; Zhang H; Zhang Z
Eur J Pharm Sci; 2019 Dec; 140():105071. PubMed ID: 31525433
[TBL] [Abstract][Full Text] [Related]
13. A Smart Paclitaxel-Disulfiram Nanococrystals for Efficient MDR Reversal and Enhanced Apoptosis.
Mohammad IS; He W; Yin L
Pharm Res; 2018 Feb; 35(4):77. PubMed ID: 29488114
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance.
Wang L; Jia E
Drug Deliv; 2016 Jun; 23(5):1810-7. PubMed ID: 26530693
[TBL] [Abstract][Full Text] [Related]
15. Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides.
Sun J; Jiang L; Lin Y; Gerhard EM; Jiang X; Li L; Yang J; Gu Z
Int J Nanomedicine; 2017; 12():1517-1537. PubMed ID: 28280323
[TBL] [Abstract][Full Text] [Related]
16. Hyaluronic acid-modified selenium nanoparticles for enhancing the therapeutic efficacy of paclitaxel in lung cancer therapy.
Zou J; Su S; Chen Z; Liang F; Zeng Y; Cen W; Zhang X; Xia Y; Huang D
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3456-3464. PubMed ID: 31469318
[TBL] [Abstract][Full Text] [Related]
17. Drug-delivering-drug approach-based codelivery of paclitaxel and disulfiram for treating multidrug-resistant cancer.
Mohammad IS; Teng C; Chaurasiya B; Yin L; Wu C; He W
Int J Pharm; 2019 Feb; 557():304-313. PubMed ID: 30599232
[TBL] [Abstract][Full Text] [Related]
18. Nanohybrid systems of non-ionic surfactant inserting liposomes loading paclitaxel for reversal of multidrug resistance.
Ji X; Gao Y; Chen L; Zhang Z; Deng Y; Li Y
Int J Pharm; 2012 Jan; 422(1-2):390-7. PubMed ID: 22001531
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation.
Ravar F; Saadat E; Gholami M; Dehghankelishadi P; Mahdavi M; Azami S; Dorkoosh FA
J Control Release; 2016 May; 229():10-22. PubMed ID: 26968799
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer.
Wang F; Li L; Liu B; Chen Z; Li C
Biomed Pharmacother; 2017 Feb; 86():595-604. PubMed ID: 28027535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]